Radiation therapy and androgen deprivation in the management of high risk prostate cancer
AUTOR(ES)
Dal Pra, Alan, Cury, Fabio L., Souhami, Luis
FONTE
International braz j urol
DATA DE PUBLICAÇÃO
2011-04
RESUMO
The combined use of radiation therapy (RT) and androgen deprivation for patients with localized high-risk prostate cancer is commonly accepted as the standard treatment among uro-oncologists. Preclinical studies have provided rationale for the use of this combination. Additionally, results of phase 3 studies using conventional doses of RT have supported the combined approach. Other phase 3 studies have also shown a benefit for using higher doses of RT; however, the role of androgen deprivation in this context is not clear. The optimal duration of the androgen deprivation, in both the neoadjuvant and adjuvant setting, is still under investigation. This article critically reviews the data on the use of RT combined with androgen deprivation for the treatment of high-risk prostate cancer with emphasis on the results of phase 3 trials.
Documentos Relacionados
- Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
- Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy
- Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study
- Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy
- External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer